Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793277 | 0.84 | GAA (0.50) | KMT2AMEN1TSHRGAACYP2D6 | |
| SCHEMBL29221790 | 0.81 | ALDH1A1 (0.62) | KMT2AMEN1TSHRGAACYP2D6 | |
| SCHEMBL23686835 | 0.79 | NPC1 (0.62) | KMT2AMEN1OPRM1OPRL1HPGD | |
| SCHEMBL7096077 | 0.79 | GAA (0.49) | KMT2AMEN1TSHRGAACYP2D6 | |
| SCHEMBL6398244 | 0.78 | NPC1 (0.50) | KMT2AMEN1TSHRALDH1A1RAB9A | |
| SCHEMBL3229771 | 0.76 | OPRM1 (0.55) | KMT2AMEN1TSHRGAACYP2D6 | |
| SCHEMBL22560026 | 0.76 | LMNA (0.62) | KMT2AMEN1TSHRGAAALDH1A1 | |
| SCHEMBL8366340 | 0.76 | TP53 (0.50) | KMT2AMEN1TSHRGAACYP2D6 | |
| SCHEMBL5013098 | 0.76 | HDAC1 (0.51) | KMT2AMEN1ALDH1A1HPGDRAB9A | |
| SCHEMBL1134867 | 0.76 | TSHR (0.60) | KMT2AMEN1TSHRGAACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | KMT2A 3968/4885MEN1 1437/4885TSHR 1034/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | KMT2A 4384/4885MEN1 1637/4885TSHR 113/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | KMT2A 4384/4885MEN1 1637/4885TSHR 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.